男女色啪网站_欧洲AⅤ亚洲AV综合在线观看_亚洲熟女中文字幕少妇_国产成人精品a视频一区

Welcome to Taixing Yangzi Pharm Chemical Co.,Ltd. official website

zzm@yzyyhg.com

+86-523-87671879 , +86-523-87679356 , +86-13905264660

NONACAP Group companies
A professional company that produces pharmaceutical intermediates

NEWS

Committed to providing excellent and reliable products and services

The industry picked up 113 stocks and won the new increase in pharmaceutical companies. Pharmaceuticals and chemicals are favored.

Time:2019-03-21

[Industry rebounded 113 stocks were newly acquired by brokers. Pharmaceutical biotechnology and chemical industry were favored] With the disclosure of the listed company's quarterly report, the changes in the shareholding of securities companies were basically presented. According to the incomplete statistics of the "Securities Daily" reporters, as of April 28, the brokerages newly entered 81 stocks, including mechanical equipment (13), chemical (7), automobiles (7), and medical biology (7). Forefront. In addition, 32 stocks were added, and medical biology (6), agriculture, forestry, animal husbandry and fishery (3), chemical industry (3), and public utilities (3) were among the top. This means that the new and increased holdings of brokerages overlap with the two major industries of pharmaceutical biology and chemical industry. (Securities Daily)

With the completion of the disclosure of the listed company's quarterly report, the changes in the shareholding of the securities companies are basically presented. According to the incomplete statistics of the "Securities Daily" reporters, as of April 28, the brokerages newly entered 81 stocks, including mechanical equipment (13), chemical (7), automobiles (7), and medical biology (7). Forefront. In addition, 32 stocks were added, and medical biology (6), agriculture, forestry, animal husbandry and fishery (3), chemical industry (3), and public utilities (3) were among the top. This means that the new and increased holdings of brokerages overlap with the two major industries of pharmaceutical biology and chemical industry.

In the first quarter, brokers' new and additional stocks all covered the chemical sector, which may be due to the advance layout of the chemical industry data. According to statistics recently released by the National Bureau of Statistics, in the first quarter of this year, the total profit of 38 industries in 41 industrial sectors increased year-on-year, of which chemical raw materials and chemical products manufacturing increased by 50.7%.

CITIC Construction Investment Research reported that the basic chemical industry expects the growth rate of the second quarter of 2017 to continue to rise. The industry indicators show that the price of viscose staple fiber has increased from 13,500 yuan/ton in March 2016 to 16716 in February 2017. Yuan/ton, returning to the rising trend.

The pharmaceutical bio-industry has also won the favor of brokers. GF ??Securities believes that under the trend of consumption upgrading, the performance of some high-end pharmaceutical consumer goods has improved significantly. Pharmaceutical consumer goods is one of the main investment lines that the pharmaceutical sector should focus on this year. In addition to pharmaceutical consumer products, the pharmaceutical sector's fine-molecular industry has a high degree of prosperity, no significant negative impact, stable net profit growth, and a reasonable valuation of the target will get good performance.

Lianxun Securities and Bio-industry Weekly believes that under the current policy of reducing drug prices as a breakthrough in medical reform, the overall drug price decline trend will not change. Some brands of Chinese medicines are more scarce in price, and the brand is deeply rooted in people's hearts. Continuity is guaranteed; in addition, some pharmaceutical white horse stocks continue to develop products and product layouts are reasonable, and the performance is less pressured by price cuts.

Relevant incomplete statistics show that the revenue growth rate of listed companies in the pharmaceutical industry in 2016 was significantly better than that in 2014 and 2015, indicating that the revenue growth rate bottomed out and returned to a good momentum. In addition, the aging of the population and the rigid demand for medical and pharmaceutical products determine the basis for long-term positive growth in revenue growth in the pharmaceutical industry.

An industry researcher from a brokerage firm believes that the machinery and equipment sector will gain double upward momentum. On the one hand, domestic urban rail transit investment is accelerating, and related businesses are increasing. On the other hand, “One Belt, One Road” drives domestic enterprises to go global, especially for rail transit. Equipment companies bring overseas incremental business, so the mechanical equipment sector has a rising base.

(Original title: 113 stocks in the industry rebounded, and new brokers increased their holdings. Pharmaceutical biotechnology and chemical industry are favored)

(Editor: DF155)